93720-89-9

Basic information

• Product Name: 2-(4-TERT-BUTYL-2,6-DIMETHYLPHENYL)ETHANAMINE
• Synonyms: 2-(4-tert-butyl-2,6-dimethylphenyl)ethan-1-amine
• CAS NO: 93720-89-9
• Molecular Formula: C₁₄H₂₃N
• Molecular Weight: 0
• Mol File: 93720-89-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 292.5°Cat760mmHg
• Flash Point: 121.5°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.00182mmHg at 25°C
• CAS DataBase Reference: 2-(4-TERT-BUTYL-2,6-DIMETHYLPHENYL)ETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-TERT-BUTYL-2,6-DIMETHYLPHENYL)ETHANAMINE(93720-89-9)
• EPA Substance Registry System: 2-(4-TERT-BUTYL-2,6-DIMETHYLPHENYL)ETHANAMINE(93720-89-9)

Safety Data

• Hazardous Substances Data: 93720-89-9(Hazardous Substances Data)

Usage

Class

Substituted phenethylamine

Psychoactive effects

Known for their psychoactive effects

Use as a selective norepinephrine releasing agent

Can stimulate the release of dopamine

Potential use in treatment

May be useful in the treatment of conditions such as ADHD or depression

Potential as a weight loss aid

Ability to suppress appetite

Side effects and health risks

Use can have significant side effects and health risks

Monitoring by medical professionals

Use should be closely monitored by medical professionals.

InChI:InChI=1/C14H23N/c1-10-8-12(14(3,4)5)9-11(2)13(10)6-7-15/h8-9H,6-7,15H2,1-5H3/p+1

Upstream product

• 84803-57-6 4-tert-butyl-2,6-dimethylphenylacetonitrile 

Downstream Products

• 208718-97-2 N-monomethyl-2-(2,6-dimethyl-4-tert-butylphenyl)-1-aminoethane 

Relevant articles and documents

Benzylimidazolines as h5-HT(1B/1D) serotonin receptor ligands: A structure-affinity investigation

Benzylimidazolines may represent a class of 5-HT(1D) ligands that has yet to be exploited. On the basis of a previous report that the 2- (substituted-benzyl)imidazoline α-adrenergic agonist oxymetazoline (8) binds with high affinity at calf brain 5-HT(1D) receptors, we explored the structure-affinity relationships of a series of related derivatives. Each of the aromatic substituents was removed and then reinstated in a systematic manner to determine the influence of the individual substituents on binding. It was found that all of the aromatic substituents of 8 act in concert to impart high affinity. However, although the 3-hydroxy group could be removed without significantly reducing affinity for h5-HT(1D) (i.e., human 5- HT(1Dα)) receptors, this modification reduced h5-HT(1B) (i.e., human 5- HT(1Dβ)) receptor affinity by nearly 50-fold. The 2,6-dimethyl groups also contribute to binding but seem to play a greater role for h5-HT(1B) binding than h5-HT(1D) binding. With the appropriate structural modifications, several compounds were identified that display 20- to > 100-fold selectivity for h5-HT(1D) versus h5-HT(1B) receptors. Preliminary functional data suggest that these compounds behave as agonists. Given that 5-HT(1D) agonists are currently being explored for their antimigraine action and that activation of h5-HT(1B) receptors might be associated with cardiovascular side effects, h5- HT(1D)selective agents may offer a new lead for the development of therapeutically efficacious agents.